Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
11.71
-2.06 (-14.96%)
At close: Mar 5, 2026, 4:00 PM EST
11.69
-0.02 (-0.17%)
After-hours: Mar 5, 2026, 7:47 PM EST
Keros Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Keros Therapeutics stock have an average target of 22.25, with a low estimate of 16 and a high estimate of 27. The average target predicts an increase of 90.01% from the current stock price of 11.71.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Keros Therapeutics stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 5 | 5 | 5 | 5 | 3 |
| Hold | 8 | 7 | 7 | 7 | 7 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 15 | 15 | 15 | 15 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $23 → $20 | Buy | Maintains | $23 → $20 | +70.79% | Mar 5, 2026 |
| B of A Securities | B of A Securities | Hold Maintains $18 → $19 | Hold | Maintains | $18 → $19 | +62.25% | Nov 28, 2025 |
| Oppenheimer | Oppenheimer | Buy Reiterates $23 → $27 | Buy | Reiterates | $23 → $27 | +130.57% | Nov 12, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $26 → $23 | Buy | Maintains | $26 → $23 | +96.41% | Nov 11, 2025 |
| Wedbush | Wedbush | Hold Maintains $15 → $16 | Hold | Maintains | $15 → $16 | +36.64% | Nov 6, 2025 |
Financial Forecast
Revenue This Year
9.81M
from 244.06M
Decreased by -95.98%
Revenue Next Year
3.01M
from 9.81M
Decreased by -69.36%
EPS This Year
-3.62
from 2.30
EPS Next Year
-4.02
from -3.62
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 60.2M | 15.8M | |||
| Avg | 9.8M | 3.0M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -75.3% | 60.5% | |||
| Avg | -96.0% | -69.4% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.34 | -2.86 | |||
| Avg | -3.62 | -4.02 | |||
| Low | -4.82 | -5.60 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.